The samples covered all breast cancer IHC subtypes including 405 hormone receptor-positive HER2 negative (HR+HER2-), 85 HR+HER2+, 66 HR-HER2+ and 81 triple-negative breast cancers (TNBCs) (Fig. 1c and Supplementary Table S1). This evidence concerns the gene ERBB2 and breast carcinoma.